Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769498 | 0.84 | PRMT6 (0.36) | PRMT6ADORA1P2RY12BMPR1B | |
| SCHEMBL12416126 | 0.82 | MAPT (0.31) | — | |
| SCHEMBL2695089 | 0.81 | PRMT6 (0.38) | PRMT6ADORA1P2RY12BMPR1B | |
| SCHEMBL12416141 | 0.80 | ADORA3 (0.40) | ADORA1P2RY12ADORA3ADORA2AADORA2B | |
| SCHEMBL26455123 | 0.74 | P2RY12 (0.38) | PRMT6ADORA1P2RY12ADORA3 | |
| SCHEMBL26435560 | 0.73 | PRMT6 (0.41) | PRMT6ADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL12416153 | 0.73 | PRMT6 (0.39) | PRMT6P2RY12ADORA3BMPR1B | |
| SCHEMBL12416136 | 0.73 | TSHR (0.42) | P2RY12ADORA3BMPR1B | |
| SCHEMBL18503746 | 0.73 | P2RY12 (0.38) | PRMT6P2RY12 | |
| SCHEMBL20248724 | 0.73 | PRMT6 (0.43) | PRMT6ADORA1P2RY12BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073786-A1 | CYCLOHEXENYL NUCLEIC ACIDS ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20110172294-A1 | CYCLOHEXENYL NUCLEIC ACIDS ANALOGS | IONIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172294-A1 | CYCLOHEXENYL NUCLEIC ACIDS ANALOGS | POLM, POLRMT, HNRNPM | PRMT6 1063/4885ADORA1 2480/4885P2RY12 4715/4885 |
| US-20140073786-A1 | CYCLOHEXENYL NUCLEIC ACIDS ANALOGS | POLM, POLRMT, HNRNPM | PRMT6 1111/4885ADORA1 2713/4885P2RY12 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.